Nirmatrelvir plus ritonavir for early COVID-19 in a large US health system: a population-based cohort study

S Dryden-Peterson, A Kim, AY Kim… - Annals of internal …, 2023 - acpjournals.org
Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …
被引用次数：118 相关文章
[HTML] nih.gov

[HTML][HTML] Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large US Health System: A Population-Based Cohort Study

S Dryden-Peterson, A Kim, AY Kim, EC Caniglia… - Annals of Internal … - ncbi.nlm.nih.gov
Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large US Health System: A Population-Based Cohort Study.

S Dryden-Peterson, A Kim, AY Kim… - Annals of Internal …, 2022 - europepmc.org
Background In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …

Nirmatrelvir plus ritonavir for early COVID-19 in a large US health system: a population-based cohort study.

S Dryden-Peterson, A Kim, AY Kim, EC Caniglia… - 2023 - cabidigitallibrary.org
Abstract Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-
Risk Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or …

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large US Health System: A Population-Based Cohort Study

S Dryden-Peterson, A Kim, AY Kim… - Annals of internal …, 2023 - pubmed.ncbi.nlm.nih.gov
Background In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large US Health System: A Population-Based Cohort Study.

S Dryden-Peterson, A Kim, AY Kim… - Ann Intern …, 2023 - pesquisa.bvsalud.org
BACKGROUND: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large US Health System: A Population-Based Cohort Study.

S Dryden-Peterson, A Kim, AY Kim… - Annals of Internal …, 2022 - europepmc.org
Background In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …